[Effect of cavinton and sulfocamphocain on systemic and cerebral hemodynamics in patients with early forms of cerebrovascular diseases].
In a study involving 33 patients with initial manifestations of inadequate cerebral blood supply and in 22 patients with transient disorders of the cerebral circulation in the presence of atherosclerosis (n = 45) and atherosclerosis with arterial hypertension (n = 8) the authors studied the effect of intravenous administration of cavinton in combination with sulfocamphocain on the clinical manifestations and on the systemic (using the method of Evans' dilution) and cerebral (using Doppler ultrasonography) hemodynamics. It has been demonstrated that both a single intravenous administration of cavinton in conjunction with sulfocamphocain and a course of treatment with these drugs reduce the volume of the circulating blood, lower the stroke and cardiac indices, increase the linear velocity of blood flow along the carotid and vertebral arteries, and decrease neurological symptomatology. The authors discuss the questions related to indications for the administration of cavinton in combination with sulfocamphocain to patients with inadequate cerebral blood supply and transient disorders of the cerebral circulation.
Ishchenko
M M
MM
Shkrobot
S I
SI
Borak
V T
VT
D002164:Camphor / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011343:Procaine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; D011343:Procaine; C013983:vinpocetine; C012050:sulfocamphocaine; D002164:Camphor
Vliianie kavintona i sul'fokamfokaina na sistemnuiu i tserebral'nuiu gemodinamiku bol'nykh s rannimi formami sosudistykh zabolevaniĭ golovnogo mozga.